TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity

British Journal of Haematology

Volumn 162, Issue 2, 2013, Pages 210-220

  Gatt, Moshe E ^a,b   Takada, Kohichi ^a,c   Mani, Mala ^a   Lerner, Mikael ^d   Pick, Marjorie ^b   Hideshima, Teru ^a   Carrasco, Daniel E ^a   Protopopov, Alexei ^a   Ivanova, Elena ^a   Sangfelt, Olle ^d   Grandér, Dan ^d   Barlogie, Bart ^e   Shaughnessy, John D ^e   Anderson, Kenneth C ^a   Carrasco, Daniel R ^a,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

13q; Myeloma; Proliferation; Proteasome; TRIM13 (RFP2)

Indexed keywords

20S PROTEASOME; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEASOME; TRIPARTITE MOTIF CONTAINING 13 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME DELETION; CHROMOSOME DELETION 13Q; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TRIPARTITE MOTIF CONTAINING 13 GENE;

13Q; MYELOMA; PROLIFERATION; PROTEASOME; TRIM13 (RFP2);

APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR SUPPRESSOR PROTEINS;

EID: 84879837065     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12365     Document Type: Article

References (45)

1. Aguilera, C., Fernandez-Majada, V., Ingles-Esteve, J., Rodilla, V., Bigas, A. & Espinosa, L. (2006) Efficient nuclear export of p65-IkappaBalpha complexes requires 14-3-3 proteins. Journal of Cell Science, 119, 3695-3704.
2. Bianchi, G., Oliva, L., Cascio, P., Pengo, N., Fontana, F., Cerruti, F., Orsi, A., Pasqualetto, E., Mezghrani, A., Calbi, V., Palladini, G., Giuliani, N., Anderson, K.C., Sitia, R. & Cenci, S. (2009) The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood, 113, 3040-3049.
3. Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., D'Urso, L., Pagliuca, A., Biffoni, M., Labbaye, C., Bartucci, M., Muto, G., Peschle, C. & De Maria, R. (2008) The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nature Medicine, 14, 1271-1277.
4. Carrasco, D.R., Tonon, G., Huang, Y., Zhang, Y., Sinha, R., Feng, B., Stewart, J.P., Zhan, F., Khatry, D., Protopopova, M., Protopopov, A., Sukhdeo, K., Hanamura, I., Stephens, O., Barlogie, B., Anderson, K.C., Chin, L., Shaughnessy, J.D. Jr, Brennan, C. & Depinho, R.A. (2006) High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell, 9, 313-325.
5. Castro-Alcaraz, S., Miskolci, V., Kalasapudi, B., Davidson, D. & Vancurova, I. (2002) NF-kappa B regulation in human neutrophils by nuclear I kappa B alpha: correlation to apoptosis. Journal of immunology, 169, 3947-3953.
6. Chng, W.J., Glebov, O., Bergsagel, P.L. & Kuehl, W.M. (2007) Genetic events in the pathogenesis of multiple myeloma. Best Practice and Research. Clinical Haematology, 20, 571-596.
7. Davenport, E.L., Moore, H.E., Dunlop, A.S., Sharp, S.Y., Workman, P., Morgan, G.J. & Davies, F.E. (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood, 110, 2641-2649.
8. Dutta-Simmons, J., Zhang, Y., Gorgun, G., Gatt, M., Mani, M., Hideshima, T., Takada, K., Carlson, N.E., Carrasco, D.E., Tai, Y.T., Raje, N., Letai, A.G., Anderson, K.C. & Carrasco, D.R. (2009) Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood, 114, 2699-2708.
9. Elnenaei, M.O., Hamoudi, R.A., Swansbury, J., Gruszka-Westwood, A.M., Brito-Babapulle, V., Matutes, E. & Catovsky, D. (2003) Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer, 36, 99-106.
10. van Everdink, W.J., Baranova, A., Lummen, C., Tyazhelova, T., Looman, M.W., Ivanov, D., Verlind, E., Pestova, A., Faber, H., van der Veen, A.Y., Yankovsky, N., Vellenga, E. & Buys, C.H. (2003) TRIM13, c13ORF1, and FAM10A4 are the most likely tumor suppressor gene candidates for B-cell chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 146, 48-57.
11. Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P.L., Chesi, M., Davies, F.E., Drach, J., Greipp, P.R., Kirsch, I.R., Kuehl, W.M., Hernandez, J.M., Minvielle, S., Pilarski, L.M., Shaughnessy, J.D. Jr, Stewart, A.K. & Avet-Loiseau, H. (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Research, 64, 1546-1558.
12. Herve, A.L., Florence, M., Philippe, M., Michel, A., Thierry, F., Kenneth, A., Jean-Luc, H., Nikhil, M. & Stephane, M. (2011) Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. Journal of Clinical Oncology, 29, 1893-1897.
13. Hideshima, T., Bradner, J.E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S.L. & Anderson, K.C. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 102, 8567-8572.
14. Huang, T.T. & Miyamoto, S. (2001) Postrepression activation of NF-kappaB requires the amino-terminal nuclear export signal specific to IkappaBalpha. Molecular and Cellular Biology, 21, 4737-4747.
15. Jagannath, S., Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Cowan, J.M. & Anderson, K.C. (2007) Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia, 21, 151-157.
16. Jahrsdorfer, B., Wooldridge, J.E., Blackwell, S.E., Taylor, C.M., Link, B.K. & Weiner, G.J. (2005) Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity. Leukemia, 19, 759-766.
17. Joo, H.M., Kim, J.Y., Jeong, J.B., Seong, K.M., Nam, S.Y., Yang, K.H., Kim, C.S., Kim, H.S., Jeong, M., An, S. & Jin, Y.W. (2011) Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2. European Journal of Cell Biology, 90, 420-431.
18. Kapanadze, B., Makeeva, N., Corcoran, M., Jareborg, N., Hammarsund, M., Baranova, A., Zabarovsky, E., Vorontsova, O., Merup, M., Gahrton, G., Jansson, M., Yankovsky, N., Einhorn, S., Oscier, D., Grander, D. & Sangfelt, O. (2000) Comparative sequence analysis of a region on human chromosome 13q14, frequently deleted in B-cell chronic lymphocytic leukemia, and its homologous region on mouse chromosome 14. Genomics, 70, 327-334.
19. Kohlhammer, H., Schwaenen, C., Wessendorf, S., Holzmann, K., Kestler, H.A., Kienle, D., Barth, T.F., Moller, P., Ott, G., Kalla, J., Radlwimmer, B., Pscherer, A., Stilgenbauer, S., Dohner, H., Lichter, P. & Bentz, M. (2004) Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood, 104, 795-801.
20. Kyle, R.A. & Rajkumar, S.V. (2004) Multiple myeloma. New England Journal of Medicine, 351, 1860-1873.
21. Lerner, M., Corcoran, M., Cepeda, D., Nielsen, M.L., Zubarev, R., Ponten, F., Uhlen, M., Hober, S., Grander, D. & Sangfelt, O. (2007) The RBCC gene TRIM13 (Leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD. Molecular Biology of the Cell, 18, 1670-1682.
22. Lia, M., Carette, A., Tang, H., Shen, Q., Mo, T., Bhagat, G., Dalla-Favera, R. & Klein, U. (2012) Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. Blood, 119, 2981-2990.
23. Mani, M., Carrasco, D.E., Zhang, Y., Takada, K., Gatt, M.E., Dutta-Simmons, J., Ikeda, H., Diaz-Griffero, F., Pena-Cruz, V., Bertagnolli, M., Myeroff, L.L., Markowitz, S.D., Anderson, K.C. & Carrasco, D.R. (2009) BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Research, 69, 7577-7586.
24. Matsuda, A., Suzuki, Y., Honda, G., Muramatsu, S., Matsuzaki, O., Nagano, Y., Doi, T., Shimotohno, K., Harada, T., Nishida, E., Hayashi, H. & Sugano, S. (2003) Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene, 22, 3307-3318.
25. Mertens, D. & Stilgenbauer, S. (2012) CLL and deletion 13q14: merely the miRs? Blood, 119, 2974-2975.
26. Mertens, D., Wolf, S., Schroeter, P., Schaffner, C., Dohner, H., Stilgenbauer, S. & Lichter, P. (2002) Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood, 99, 4116-4121.
27. Mitsiades, C.S., Mitsiades, N., Munshi, N.C. & Anderson, K.C. (2004) Focus on multiple myeloma. Cancer Cell, 6, 439-444.
28. Nakamura, M., Gotoh, T., Okuno, Y., Tatetsu, H., Sonoki, T., Uneda, S., Mori, M., Mitsuya, H. & Hata, H. (2006) Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells. Leukaemia & Lymphoma, 47, 531-539.
29. Nelson, E.A., Walker, S.R., Kepich, A., Gashin, L.B., Hideshima, T., Ikeda, H., Chauhan, D., Anderson, K.C. & Frank, D.A. (2008) Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood, 112, 5095-5102.
30. Protopopov, A.I., Gizatullin, R.Z., Vorobieva, N.V., Protopopova, M.V., Kiss, C., Kashuba, V.I., Klein, G., Kisselev, L.L., Graphodatsky, A.S. & Zabarovsky, E.R. (1996) Human chromosome 3: high-resolution fluorescence in situ hybridization mapping of 40 unique NotI linking clones homologous to genes and cDNAs. Chromosome Research, 4, 443-447.
31. Rajkumar, S.V., Fonseca, R., Dewald, G.W., Therneau, T.M., Lacy, M.Q., Kyle, R.A., Greipp, P.R. & Gertz, M.A. (1999) Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genetics and Cytogenetics, 113, 73-77.
32. Rizzatti, E.G., Mora-Jensen, H., Weniger, M.A., Gibellini, F., Lee, E., Daibata, M., Lai, R. & Wiestner, A. (2008) Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leukaemia & Lymphoma, 49, 798-808.
33. Sagaster, V., Ludwig, H., Kaufmann, H., Odelga, V., Zojer, N., Ackermann, J., Kuenburg, E., Wieser, R., Zielinski, C. & Drach, J. (2007) Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia, 21, 164-168.
34. Schop, R.F., Jalal, S.M., Van Wier, S.A., Ahmann, G.J., Bailey, R.J., Kyle, R.A., Greipp, P.R., Rajkumar, S.V., Gertz, M.A., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Witzig, T.E. & Fonseca, R. (2002) Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genetics and Cytogenetics, 132, 55-60.
35. Shaffer, A.L., Emre, N.C., Lamy, L., Ngo, V.N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., Zeng, Y., Chen, B., Epstein, J. & Staudt, L.M. (2008) IRF4 addiction in multiple myeloma. Nature, 454, 226-231.
36. Shaughnessy, J. Jr, Tian, E., Sawyer, J., McCoy, J., Tricot, G., Jacobson, J., Anaissie, E., Zangari, M., Fassas, A., Muwalla, F., Morris, C. & Barlogie, B. (2003) Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. British Journal of Haematology, 120, 44-52.
37. Shaughnessy, J.D. Jr, Zhan, F., Burington, B.E., Huang, Y., Colla, S., Hanamura, I., Stewart, J.P., Kordsmeier, B., Randolph, C., Williams, D.R., Xiao, Y., Xu, H., Epstein, J., Anaissie, E., Krishna, S.G., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J. & Barlogie, B. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 109, 2276-2284.
38. Shen, Y., Ballar, P., Apostolou, A., Doong, H. & Fang, S. (2007) ER stress differentially regulates the stabilities of ERAD ubiquitin ligases and their substrates. Biochemical and Biophysical Research Communications, 352, 919-924.
39. Sorriento, D., Ciccarelli, M., Santulli, G., Campanile, A., Altobelli, G.G., Cimini, V., Galasso, G., Astone, D., Piscione, F., Pastore, L., Trimarco, B. & Iaccarino, G. (2008) The G-protein-coupled receptor kinase 5 inhibits NFkappaB transcriptional activity by inducing nuclear accumulation of IkappaB alpha. Proceedings of the National Academy of Sciences of the United States of America, 105, 17818-17823.
40. Sukhdeo, K., Mani, M., Zhang, Y., Dutta, J., Yasui, H., Rooney, M.D., Carrasco, D.E., Zheng, M., He, H., Tai, Y.T., Mitsiades, C., Anderson, K.C. & Carrasco, D.R. (2007) Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 104, 7516-7521.
41. Tonon, G. (2007) Molecular pathogenesis of multiple myeloma. Hematology/oncology Clinics of North America, 21, 985-1006, vii.
42. Vu, H.Y., Juvekar, A., Ghosh, C., Ramaswami, S., Le, D.H. & Vancurova, I. (2008) Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha. Archives of Biochemistry and Biophysics, 475, 156-163.
43. Wang, Q., Mora-Jensen, H., Weniger, M.A., Perez-Galan, P., Wolford, C., Hai, T., Ron, D., Chen, W., Trenkle, W., Wiestner, A. & Ye, Y. (2009) ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 106, 2200-2205.
44. Willis, T.G., Zalcberg, I.R., Coignet, L.J., Wlodarska, I., Stul, M., Jadayel, D.M., Bastard, C., Treleaven, J.G., Catovsky, D., Silva, M.L. & Dyer, M.J. (1998) Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood, 91, 1873-1881.
45. Zent, C.S., Zhan, F., Schichman, S.A., Bumm, K.H., Lin, P., Chen, J.B. & Shaughnessy, J.D. (2003) The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. Leukemia Research, 27, 765-774.